Sign In
Buy REGN
$618.95
+16.03 (+2.66%)
At Close: Jun 03, 2026
Analyst Ratings for Regeneron Pharmaceuticals
04:23pm, Friday, 09'th Sep 2022 Benzinga
Within the last quarter, Regeneron Pharmaceuticals (NASDAQ:REGN) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
0
3
6
Three Stock Lunch: Regeneron, Match Group and Caesars Entertainment
03:50pm, Friday, 09'th Sep 2022
Tim Seymour, Seymour Asset Management CIO and CNBC contributor, joins 'Power Lunch' to discuss his investing take on three stocks; Regeneron, Match Group and Caesars Entertainment.
Morgan Stanley just upgraded this large cap biotech stock
02:54pm, Friday, 09'th Sep 2022
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) is now back to near its year-to-date high but a Morgan Stanley analyst says the stock is not done pleasing its investors yet.
Regeneron Gets Praised by Wall Street. High-Dose Eylea Data Look 'Strong.
11:02am, Friday, 09'th Sep 2022
Jefferies upgrades the stock and other analysts raise their price targets on Regeneron following better-than-expected data on a new formulation of the company's signature eye medication.
Regeneron Announces Investor Call and Webcast at ESMO 2022
10:00am, Friday, 09'th Sep 2022
TARRYTOWN, N.Y. , Sept. 9, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will host a conference call and simultaneous webcast to share updates on the company's oncology portfolio
Regeneron (REGN) Up on Higher Dose Eye Drug Studies Success
09:47am, Friday, 09'th Sep 2022
Regeneron (REGN) stock jumps as aflibercept 8 mg with 12- and 16-week dosing regimens in patients with DME and wAMD meet primary goals.
Regeneron stock surges on positive results in eye disease drug trial
04:04pm, Thursday, 08'th Sep 2022
Yahoo Finance Live examines Regeneron Pharmaceuticals' stock following reports of positive results in its eye treatment drug trials.
Regeneron Pharmaceuticals, Inc. (REGN) 2022 Wells Fargo Healthcare Conference (Transcript)
02:56pm, Thursday, 08'th Sep 2022
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) 2022 Wells Fargo Healthcare Conference September 8, 2022 11:00 AM ET Company Participants Ryan Crowe - Head, IR Robert Landry - CFO Conference Call Parti
Why Regeneron Pharmaceuticals Stock Is Crushing It Today
02:32pm, Thursday, 08'th Sep 2022
The biotech's crown jewel scores a key win in the clinic.
Regeneron Stock Surges on Promising Eye Disease Drug Trial
11:05am, Thursday, 08'th Sep 2022
Regeneron announces promising results from late-stage clinical trials on its signature eye drug medication, Eylea.
Stocks fluctuate, Regeneron stock surges, oil above $83 a barrel
10:46am, Thursday, 08'th Sep 2022
Yahoo Finance's Ines Ferré discusses how markets are moving in early trading.
Regeneron says Eylea met the primary endpoints in two trials
09:23am, Thursday, 08'th Sep 2022
Regeneron Pharmaceuticals Inc. REGN, +3.91% said Thursday that an 8-milligram dose of aflibercept successfully treated patients with diabetic macular edema and wet age-related macular degeneration in
Regeneron (REGN) Down 2.3% Since Last Earnings Report: Can It Rebound?
03:31pm, Friday, 02'nd Sep 2022 Zacks Investment Research
Regeneron (REGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Regeneron (REGN) Down 2.3% Since Last Earnings Report: Can It Rebound?
12:48pm, Friday, 02'nd Sep 2022
Regeneron (REGN) reported earnings 30 days ago. What's next for the stock?
Should Invesco S&P 500 GARP ETF (SPGP) Be on Your Investing Radar?
10:20am, Monday, 29'th Aug 2022 Zacks Investment Research
Style Box ETF report for SPGP
